文献速递系统性红斑狼疮

糖皮质激素剂量对狼疮性肾炎初始治疗中完全缓解、严重感染与死亡率的影响:随机对照试验对照组的系统评价与Meta分析

Impact of Glucocorticoid Dose on Complete Response, Serious Infections, and Mortality During the Initial Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis of the Control Arms of Randomized Controlled Trials.
PubMed 文献 · Arthritis Rheumatol · 2024-06-28

该系统评价与Meta分析纳入50项随机对照试验的对照组共3231例经活检证实的狼疮性肾炎患者,评估初始糖皮质激素方案对完全缓解、严重感染和死亡的影响。起始泼尼松25 mg/d不冲击时完全缓解、严重感染和死亡的预测率分别为19.5%、3.2%和0.2%;起始60 mg/d不冲击时分别升至34.6%、12.1%和2.7%;加用糖皮质激素冲击可提高完全缓解和死亡但未提高严重感染。初始糖皮质激素暴露较高与肾脏结局较好相关,但以感染和死亡增加为代价。

要点

  • 起始泼尼松25 mg/d不冲击时完全缓解率19.5%、严重感染率3.2%、死亡率0.2%。
  • 起始泼尼松60 mg/d不冲击时完全缓解率34.6%、严重感染率12.1%、死亡率2.7%。
  • 加用糖皮质激素冲击可提高完全缓解和死亡但未提高严重感染。

核心结论

  • 狼疮性肾炎初始治疗中较高的糖皮质激素暴露与较好的肾脏结局相关,但以感染和死亡增加为代价。

研究设计与样本

  • 系统评价与Meta分析,纳入50项随机对照试验的对照组,共3231例经活检证实的狼疮性肾炎患者。
  • 纳入的随机对照试验使用protocolized糖皮质激素方案联合霉酚酸类似物或环磷酰胺,并报告完全缓解、严重感染和死亡结局。
  • 提取糖皮质激素起始剂量、减量方法和是否给予糖皮质激素冲击,在6个月和12个月对所有结局进行比例Meta分析、Meta回归和亚组Meta分析。

主要发现

  • 起始口服泼尼松25 mg/d不冲击时,完全缓解、严重感染和死亡的预测率分别为19.5%(95%CI 7.3-31.5)、3.2%(95%CI 2.4-4.0)和0.2%(95%CI 0.0-0.4)。
  • 起始泼尼松60 mg/d不冲击时,完全缓解、严重感染和死亡的预测率分别升至34.6%(95%CI 16.9-52.3)、12.1%(95%CI 9.3-14.9)和2.7%(95%CI 0.0-5.3)。
  • 加用糖皮质激素冲击可提高完全缓解和死亡但未提高严重感染。
  • 在6个月时,校正糖皮质激素冲击、基础免疫抑制剂和基线蛋白尿后,观察到初始糖皮质激素剂量与所有结局之间存在剂量-反应梯度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our objective was to evaluate the effect of glucocorticoid regimens on renal response, infections, and mortality among patients with lupus nephritis (LN). METHODS: We performed a systematic review and meta-analysis of the control arms of randomized clinical trials (RCTs). We included RCTs of biopsy-proven LN that used a protocolized regimen of glucocorticoids in combination with mycophenolic acid analogs or cyclophosphamide and reported the outcomes of complete response (CR), serious infections, and death. The starting dosage of glucocorticoids, tapering method, and administration of glucocorticoid pulses were abstracted. Meta-analysis of proportions, meta-regression, and subgroup meta-analysis were performed at 6 and 12 months for all outcomes. RESULTS: Fifty RCT arms (3,231 patients with LN) were included. The predicted rates of CR, serious infections, and death when starting on oral prednisone at 25 mg/day without pulses were 19.5% (95% confidence interval [CI] 7.3-31.5), 3.2% (95% CI 2.4-4.0), and 0.2% (95% CI 0.0-0.4), respectively. Starting on prednisone at 60 mg/day (without pulses) increased the rates to 34.6% (95% CI 16.9-52.3), 12.1% (95% CI 9.3-14.9), and 2.7% (95% CI 0.0-5.3), respectively. Adding glucocorticoid pulses increased the rates of CR and death but not serious infections. We observed a dose-response gradient between the initial glucocorticoid dosage and all the outcomes at six months after accounting for the administration of glucocorticoid pulses, underlying immunosuppressant, and baseline proteinuria. CONCLUSION: A higher exposure to glucocorticoids during the initial therapy of LN was associated with better renal outcomes at the cost of increased infections and death.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Figueroa-Parra G, Cuéllar-Gutiérrez MC, González-Treviño M, et al. Impact of Glucocorticoid Dose on Complete Response, Serious Infections, and Mortality During the Initial Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis of the Control Arms of Randomized Controlled Trials. Arthritis Rheumatol. 2024. PMID: 38766897. doi:10.1002/art.42920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。